LCTX
Lineage Cell Therapeutics Inc
NYSE MKT: LCTX · HEALTHCARE · BIOTECHNOLOGY
$1.43
-2.05% today
Updated 2026-05-06
Market cap
$363.98M
P/E ratio
—
P/S ratio
25.01x
EPS (TTM)
$-0.28
Dividend yield
—
52W range
$0 – $2
Volume
1.2M
Lineage Cell Therapeutics Inc (LCTX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
—
Last 4 quarters
Revenue YoY growth
+130.4%
Most recent quarter
EPS YoY growth
+135.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-4.2%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-5.1%
2026-03-05
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-05 | $0.00 | +107.7% | $1.95 | $1.85 | -5.1% |
| 2025-11-06 | $-0.13 | -550.0% | $1.82 | $1.76 | -3.3% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.05 | $0.00 | +107.7% | $6.61M | +130.4% |
| 2025-09-30 | $-0.02 | $-0.13 | -550.0% | $3.68M | -2.6% |
| 2025-06-30 | $-0.03 | $-0.13 | -333.3% | $2.77M | +96.4% |
| 2025-03-31 | $-0.03 | $-0.02 | +28.6% | $1.50M | +4.0% |
| 2024-12-31 | $-0.03 | $-0.01 | +66.7% | $2.87M | +37.4% |
| 2024-09-30 | $-0.04 | $-0.02 | +50.0% | $3.78M | +203.3% |
| 2024-06-30 | $-0.05 | $-0.03 | +40.0% | $1.41M | -56.3% |
| 2024-03-31 | $-0.04 | $-0.04 | +0.0% | $1.44M | -39.5% |
| 2023-12-31 | $-0.04 | $-0.03 | +25.0% | $2.09M | — |
| 2023-09-30 | $-0.04 | $-0.04 | +0.0% | $1.25M | — |
| 2023-06-30 | $-0.04 | $-0.03 | +25.0% | $3.23M | — |
| 2023-03-31 | $-0.04 | $-0.03 | +25.0% | $2.39M | — |
Frequently asked questions
Has Lineage Cell Therapeutics Inc beaten earnings estimates?
Lineage Cell Therapeutics Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports.
How does LCTX stock react to earnings?
LCTX stock has moved an average of -4.2% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is Lineage Cell Therapeutics Inc's revenue growth rate?
Lineage Cell Therapeutics Inc reported year-over-year revenue growth of +130.4% in its most recent quarter, with EPS growing +135.0% year-over-year.